You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
据报开拓药业(09939.HK)新冠疫苗临床试验报告受质疑
阿思达克 05-14 10:59
开拓药业(09939.HK)於上月25日公布在美国进行用於治疗轻中症男性新冠肺炎患者的普克鲁胺3期临床测试已完成首位患者入组及给药後,带动股价急升。但《路透社》报道,开拓药业首席临床试验研究员Zeid Kayali表示,自己没有负责该临床试验,截至5月初开拓药业亦根本没有给任何患者服药。

开拓药业财务总监卢燕表示,Kayali只是临床试验研究员之一,不会就上月25日有关患者用药的公告发表进一步评论,同时拒绝透露其他首席研究员或负责临床试验机构的资料,称这是公司的机密资料。

根据开拓药业在美国临床试验网站上发布的文件,Zeid Kayali确实是被列为首席临床试验研究员;同时许多药厂亦会提供领导临床试验研究员的资料,以及负责测试的研究组织或医疗机构的名称,以确保科学有效性及患者的安全。

开拓药业在3月时公布於巴西进行的临床测试结果,发现可降低92%患者死亡风险,但目前普克鲁胺仍未有获得监管部门批准,同时在巴西的临床测试亦尚未经过同行审阅。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account